EGFR and head and neck squamous cell carcinoma: After checking the effective antitumor effects on preclinical HNSCC models, a phase 1 TRIAL (with a cohort of 11 patients) was carried out to verify whether systemic administration of Cetuximab RT combined with intratumoral injections of EGFR-AS effectively increased the antitumor effects of the current elective therapy, particularly at locoregional level.